FATE THERAPEUTICS INC

Listed Company

FATECIK 0001434316NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)FY ends Dec 31

Period

FY 2025

Revenue

$6.65M

Net Income

$-136.31M

Total Assets

$318.94M

Equity

$207.18M

Shares Out

116.26M

Op. Cash Flow

$-106.08M

Business

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies by engineering induced pluripotent stem cells (iPSCs) to incorporate synthetic controls of cell function. It develops multiplexed-engineered iPSC-derived T-cell and natural killer (NK) product candidates, including CAR T and CAR NK therapies that incorporate technologies such as ADR, hnCD16 and Sword & Shield. The company’s operations center on research and development programs, clinical-stage product candidates, proprietary platform and in-house GMP manufacturing, and strategic collaborations. It distributes investigational products through clinical trials and plans off-the-shelf delivery via its GMP facility and third‑party CMOs to hospitals and treatment centers internationally.

Summary from filing dated 2025-03-05

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	7	14	64	96	56
Research and development	108	135	173	320	216
General and administrative	47	74	81	84	57
Impairment loss	0	15	0	—	—
Total operating expenses	154	224	254	405	273
Loss from operations	−148	−210	−191	−308	−217
Interest income	11	17	17	6	1
Change in fair value of stock price appreciation milestones	244,000	819,000	3	20	4
Other income	93,000	6	10	516,000	0
Total other income	11	24	30	27	5
Net loss	−136	−186	−161	−282	−212
Unrealized gain (loss) on available-for-sale securities, net	−152,000	253,000	2	−1	−832,000
Comprehensive loss	−136	−186	−159	−283	−213
Net loss per share, Basic	−1.15	−1.64	−1.64	−2.91	−2.24
Net loss per share, Diluted	−1.15	−1.64	−1.64	−2.91	−2.24
Weighted-average common shares used to compute basic net loss per share	119	114	98	97	95
Weighted-average common shares used to compute diluted net loss per share	119	114	98	97	95

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	47	36	42	61	134
Accounts receivable	916,000	4	2	38	9
Short-term investments	157	243	273	375	482
Prepaid expenses and other current assets	4	9	15	27	9
Total current assets	209	292	332	502	633
Long-term investments	1	28	980,000	5	101
Property and equipment, net	57	64	97	110	92
Operating lease right-of-use assets	42	47	62	66	71
Restricted cash	10	10	15	15	15
Other assets	0	9,000	9,000	33,000	33,000
Total assets	319	441	506	706	921
Accounts payable	3	9	5	8	9
Accrued expenses	20	21	28	54	42
CIRM award liability, current portion	8	0	0	4	3
Deferred revenue	381,000	393,000	685,000	42	21
Operating lease liabilities, current portion	5	7	6	6	6
Total current liabilities	36	39	39	114	81
CIRM award liability, net of current portion	2	5	0	0	800,000
Operating lease liabilities, net of current portion	73	78	97	104	109
Stock price appreciation milestones	283,000	527,000	1	4	24
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value; authorized shares - 5,000,000; Class A Convertible Preferred shares issued and outstanding - 2,755,086 at December 31, 2025 and December 31, 2024	3,000	3,000	3,000	3,000	3,000
Common stock, $0.001 par value; authorized shares - 350,000,000 at December 31, 2025 and 250,0000,000 at December 31, 2024; issued and outstanding - 115,359,735 at December 31, 2025 and 113,928,279 at December 31, 2024	115,000	114,000	99,000	97,000	96,000
Additional paid-in capital	1,741	1,716	1,580	1,536	1,449
Accumulated other comprehensive income	116,000	268,000	15,000	−2	−762,000
Accumulated deficit	−1,534	−1,398	−1,212	−1,051	−769
Total stockholders equity	207	319	368	484	679
Total liabilities and stockholders equity	319	441	506	706	921

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−136	−186	−161	−282	−212
Depreciation and amortization	13	19	18	14	6
Stock-based compensation	25	41	43	79	54
Accretion and amortization of premiums and discounts on investments, net	−4	−9	−11	−256,000	5
Deferred revenue	−12,000	−892,000	−42	−6	−19
Loss on disposal of property and equipment	9,000	942,000	0	—	—
Accounts receivable	3	−1	37	−30	−3
Prepaid expenses and other assets	5	5	13	−18	−3
Accounts payable and accrued expenses	−9	−2	−29	14	6
Right-of-use assets and lease liabilities, net	−3	−4	−1	−828,000	2
Net cash used in operating activities	−106	−123	−132	−248	−163
Proceeds from sale of property and equipment	362,000	0	—	—	—
Purchases of property and equipment	−6	−730,000	−6	−36	−51
Purchases of investments	−195	−318	−359	−405	−968
Maturities of investments	312	331	478	607	695
Net cash provided by investing activities	111	12	113	167	−324
Issuance of common stock from equity incentive plans, net of issuance costs	0	295,000	85,000	9	21
Proceeds from public offering of common stock, net of issuance costs	0	75	0	—	—
Proceeds from issuance of pre-funded warrants, net of issuance costs	0	20	0	0	21
Proceeds from FT819 CIRM award	1	5	—	—	—
Proceeds from FT836 CIRM award	4	0	—	—	—
Net cash provided by financing activities	5	100	85,000	9	453
Net change in cash, cash equivalents and restricted cash	11	−11	−20	−72	−34
Purchases of property and equipment in accounts payable	0	140,000	0	1	4

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro